Splice-Switching Therapy for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a genetic disorder with severity ranging from premature death in infants to restricted motor function in adult life. Despite the genetic cause of this disease being known for over twenty years, only recently has a therapy been approved to treat the most severe form o...
Main Authors: | Katharina E. Meijboom, Matthew J.A. Wood, Graham McClorey |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-06-01
|
Series: | Genes |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4425/8/6/161 |
Similar Items
-
Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy
by: Jan Lejman, et al.
Published: (2021-08-01) -
Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
by: Valérie Robin, et al.
Published: (2017-06-01) -
Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides
by: Suzan M Hammond, et al.
Published: (2014-01-01) -
Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
by: Audrey M. Winkelsas, et al.
Published: (2021-03-01) -
A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
by: Jeffrey M Keil, et al.
Published: (2014-01-01)